跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ZYNRELEF - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ZYNRELEF
Authorized
STANDARD
ZYNRELEF
Heron Therapeutics, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
1a900da5b482a0a3
Company
Heron Therapeutics, Inc.
Type
Standard
Approval Details
Approval Id
1a900da5b482a0a3
Drug Approval Canada Name
ZYNRELEF
Product Name
ZYNRELEF
Status
Cancelled Pre Market
Status Date
2023-06-29
Din
02525968
Drug Class
Human
Dosage Form
Solution (Extended Release)
Route Of Administration
Instillation
Schedule
Prescription
Ahfs
72:00.00
Atc Original
N01BB59 BUPIVACAINE AND MELOXICAM
Atc Name
n 01 bb 59
Aig Number
0263461003
Company Name
Heron Therapeutics, Inc.
Company Address
200, 4242 Campus Point Court, San Diego, California, United States, 92121
Company Detail Path
/organization/heron-therapeutics-inc
Company Information
Pharmaceutical Company Name
Heron Therapeutics, Inc.
Country Name
United States
Province Name
California
City Name
san diego,california,country_us
Address
4242 Campus Point Ct Ste 200
Website
http://www.herontx.com
Active Ingredients
BUPIVACAINE
60 MG / 2.3 ML
MELOXICAM
1.8 MG / 2.3 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
1a900da5b482a0a3
Type
Standard
Back to Health Canada Approvals